相关实验视频
Updated: Sep 15, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
护士指导的胰岛素协议在危急病患者中控制高血糖的疗效
Nafisa Moustafa Abdallah Elpasiony1, Ahmed Ali Hafez2, Abdelaziz Hendy3
1Medical Surgical Nursing, Faculty of Nursing, Beni-Suef University, Beni-Suef, Egypt.
BMC nursing
|July 15, 2025
概括
护士领导的胰岛素方案显著改善了重症患者的血糖控制,减少了重症监护室 (ICU) 停留时间. 与传统的医生主导护理相比,这种方法为管理高血糖提供了更有效的策略.
科学领域:
- 关键护理医学 关键护理医学
- 内分泌学 在内分泌学.
- 护理实践 护理实践
背景情况:
- 过高血糖在危急病患者中很常见,与不良结果相关.
- 医生主导的胰岛素管理可能比护士主导的协议反应较弱.
- 护士领导的协议提供了一个及时的方法来控制ICU中的血糖.
研究的目的:
- 为了评估护士领导的胰岛素输注协议的有效性.
- 为了比较护士主导的管理与传统的医生指导的高血糖治疗.
- 评估对血糖控制和ICU停留时间的影响.
主要方法:
- 在ICU环境中准实验性设计.
- 80名患有高血糖症的成年患者随机分为两组 (每组n=40).
- 干预:护士领导的胰岛素输注方案;控制:标准护理.
主要成果:
- 干预组的血糖控制明显改善 (p < 0.001).
- 62.5%的干预患者在1-2天内达到目标血糖,对照组为12.5%.
- 减少了ICU停留时间:52.5%的干预组停留了3-4天,而对照组的相同比例停留了7天 (p < 0.001).
结论:
- 护士主导的胰岛素方案显著改善了重症患者的血糖控制.
- 这些协议有效地减少了ICU停留时间.
- 结合护士领导的协议,优化了ICU患者的治疗结果和资源使用.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
263
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
263
Hypoglycemia and Glucagon
342
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
342
Diabetes: Management and Pharmacotherapy
402
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
402
Oral Hypoglycemic Agents: Glinides
268
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
268
Insulin Formulations: Types and Delivery
274
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
274
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K

